
A study published in the Journal of Intensive Care Medicine examined the association between biomarker-concordant corticosteroid treatment and outcomes in patients with severe COVID-19. The study included adult COVID-19 hospitalized patients from 109 institutions between January 2020 and December 2021. The study found that corticosteroid treatment concordant with biomarker levels was associated with lower in-hospital mortality compared to discordant treatment. The effect was more pronounced as C-reactive protein (CRP) levels increased. Biomarker-concordant steroid use was also linked to a lower need for invasive ventilation. However, no benefit was observed at a CRP threshold of 50. The study highlights the importance of tailoring corticosteroid treatment based on biomarker levels in severe COVID-19 cases.
Like
Save
Share